Liquidia Corporation
LQDA
$-0.46
Change (1 day)
$19.41
Year High
$8.26
Year Low
Categories
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
P/S ratio for Liquidia Corporation (LQDA)
P/S ratio as of 2024: 66.13
According to Liquidia Corporation's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 66.13. At the end of 2023 the company had a P/S ratio of 44.71.
P/S ratio history for Liquidia Corporation from 2016 to 2024
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2024 | 66.13 |
| 2023 | 44.71 |
| 2022 | 24.37 |
| 2021 | 18.82 |
| 2020 | 135.16 |
| 2019 | 9.79 |
| 2018 | 57.32 |
| 2017 | 13.13 |
| 2016 | 4.27 |